Mereo Biopharma Group Plc ADR (MREO) concluded trading on Thursday at a closing price of $2.41, with 2.74 million shares of worth about $6.6 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -40.49% during that period and on March 27, 2025 the price saw a gain of about 1.69%. Currently the company’s common shares owned by public are about 154.73M shares, out of which, 142.29M shares are available for trading.
Stock saw a price change of -5.86% in past 5 days and over the past one month there was a price change of -1.63%. Year-to-date (YTD), MREO shares are showing a performance of -31.14% which decreased to -18.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.22 but also hit the highest price of $5.02 during that period. The average intraday trading volume for Mereo Biopharma Group Plc ADR shares is 1.22 million. The stock is currently trading -2.94% below its 20-day simple moving average (SMA20), while that difference is down -11.92% for SMA50 and it goes to -34.37% lower than SMA200.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) currently have 154.73M outstanding shares and institutions hold larger chunk of about 66.45% of that.
The stock has a current market capitalization of $372.90M and its 3Y-monthly beta is at 0.63. It has Quick Ratio of 6.10 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MREO, volatility over the week remained 7.81% while standing at 6.23% over the month.
Stock’s fiscal year EPS is expected to rise by 20.83% while it is estimated to increase by 42.86% in next year. EPS is likely to grow at an annualized rate of 44.97% for next 5-years, compared to annual growth of 41.78% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on March 27, 2025 offering an Overweight rating for the stock and assigned a target price of $7 to it. Coverage by Jefferies stated Mereo Biopharma Group Plc ADR (MREO) stock as a Buy in their note to investors on December 06, 2024, suggesting a price target of $7 for the stock. On June 13, 2024, Robert W. Baird Initiated their recommendations, while on October 13, 2023, BTIG Research Resumed their ratings for the stock with a price target of $4. Stock get an Overweight rating from Cantor Fitzgerald on August 12, 2022.
